Journal of Hematology & Oncology · 2023 · 36 citations · 58 references
MedicineHematologyImmunologyCancer ImmunologyCell TherapyImmunotherapyCancer ImmunotherapyCell-based ImmunotherapyCellular TherapyChimeric Antigen Receptor T-cell TherapyDose EscalationHematologic Malignancy TherapyAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentB-cell Malignancy Cellular TherapyCar T Cell TrialsClinical Trial Efficacy EvaluationRelapsed Acute Lymphoblastic LeukemiaT-cell Receptor Engineered T-cell TherapyT-cell Therapy
BACKGROUND: Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or relapsed (r/r) acute lymphoblastic leukemia (ALL). METHODS: . Leukapheresis, manufacturing and administration of CARTs were performed in-house. RESULTS: For all patients, CART manufacturing was feasible. None of the patients developed any grade of Immune effector cell-associated neurotoxicity syndrome (ICANS) or a higher-grade (≥ grade III) catokine release syndrome (CRS). CART expansion and long-term CART persistence were evident in the peripheral blood (PB) of evaluable patients. At end of study on day 90 after CARTs, ten patients were evaluable for response: Eight patients (80%) achieved a complete remission (CR), including five patients (50%) with minimal residual disease (MRD)-negative CR. Response and outcome were associated with the administered CART dose. At 1-year follow-up, median overall survival was not reached and progression-free survival (PFS) was 38%. Median PFS was reached on day 120. Lack of CD39-expression on memory-like T cells was more frequent in CART products of responders when compared to CART products of non-responders. After CART administration, higher CD8 + and γδ-T cell frequencies, a physiological pattern of immune cells and lower monocyte counts in the PB were associated with response. CONCLUSION: In conclusion, third-generation CARTs were associated with promising clinical efficacy and remarkably low procedure-specific toxicity, thereby opening new therapeutic perspectives for patients with r/r ALL. Trial registration This trial was registered at www. CLINICALTRIALS: gov as NCT03676504.
58
UMAP: Uniform Manifold Approximation and Projection
Leland McInnes, John Healy, Nathaniel Saul et al. · The Journal of Open Source Software · 2018 · 9.6K citations · Full text
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al. · New England Journal of Medicine · 2018 · 5.6K citations · Full text
Medicine, Hematology, Oncology +17
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles, Aaron M. Newman, Chih Long Liu et al. · Nature Medicine · 2015 · 3.3K citations · Full text
Medicine, Cancer Biology, Oncology +16